Last updated: 11/07/2018 16:01:12

A study to assess the bioavailability of fluticasone proprionate from a CFC metered dose inhaler containing 1% lecithin

GSK study ID
C92-079
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A study to assess the bioavailability of fluticasone proprionate from a CFC metered dose inhaler containing 1% lecithin
Trial description: A study to assess the bioavailability of fluticasone proprionate from a CFC metered dose inhaler containing 1% lecithin
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Lower systemic exposure and reduced systemic pharmacodynamic effects from a combination salmeterol/fluticasone propionate metered-dose inhaler compared individual inhalers in healthy subjects. RL Kunka Y Yin SMS Andrews M York Karen Callahan-Y S KirbyC PT Daley-Yates::G, 58th Annual Meeting of the American Academy of Allergy, Asthma and Immunology 3/1/2002 New York, NY; USA
Mackie AE, McDowall JE, Ventresca GP, Bye A, Falcoz C and Daley-Yates PT. Pharmacokinetics and systemic pharmacodynamic profile of fluticasone propionate administered via metered dose inhalers containing chlorofluorocarbon or hydrofluoroalkane propellants. Clin. Pharmacokinet 39 (Suppl. 1):17-22, 2000
Medical condition
Asthma
Product
fluticasone propionate
Collaborators
Not applicable
Study date(s)
May 1993 to May 1993
Type
Not applicable
Phase
1

Participation criteria

Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Not applicable

Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1993-29-05

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website